Caremark: Higher Medicare Prices, a Smaller Commercial Bill

In the Caremark cross-book pricing judgment case, a federal court ordered pharmacy benefit manager Caremark to pay $289,873,500 for causing false Medicare Part D price reports. Higher Part D payments to Walgreens and Rite Aid reduced what Caremark owed those pharmacies on its commercial business. The savings benefited Caremark, while the reports used to calculate Medicare subsidies left out the offset. Taxpayers covered the inflated drug costs. An insider who sees both books can recognize what a single prescription payment conceals.

The August 19, 2025 district-court judgment concerned reporting for 2013 and 2014. Caremark supplied the pricing information. Aetna and SilverScript, the Part D plan sponsors, used that information in reports to the Centers for Medicare and Medicaid Services.

The whistleblower was an actuary in Aetna’s Medicare department. According to the court’s trial findings, her comparison of publicly available drug prices initially raised a business question about Aetna’s competitiveness. Caremark’s explanation of the relationship between commercial and Medicare prices turned it into a compliance concern. She brought the qui tam case, and the government declined to join it.

How Commercial and Part D Pricing Met

Caremark’s contracts with Walgreens and Rite Aid tied commercial and Medicare Part D purchases to one annual average-price commitment. Paying more on the Medicare side could reduce the year-end payment needed to meet that commitment on the commercial side.

The contracts expressed their annual minimum as a generic effective rate, usually a discount off average wholesale price. A generic effective rate measures the average price across a group of drugs. Maximum allowable cost pricing, commonly called MAC pricing, sets prices for individual purchases. Caremark controlled those MAC prices and could set different rates for Medicare and commercial business.

The pharmacy contracts promised a minimum average payment across both books. If Caremark’s combined payments fell below that average, it owed the pharmacy a year-end reconciliation payment. The contracts also allowed Caremark to offset commercial underpayments with Part D overpayments, measured against the agreed average.

That offset changed the economics of pass-through pricing. Aetna and SilverScript’s Part D contracts called for Caremark to pass through the pharmacy price. Aetna also paid an administrative fee. Caremark could retain a spread on commercial drugs. Raising the Part D price reduced the commercial shortfall it had to fund, increasing the spread it could keep on that business.

The court’s account of Rite Aid’s reconciliation for 2013 makes the effect concrete. Relative to the agreed average, Caremark underpaid on commercial drugs by over $51 million and overpaid on Part D drugs by some $44 million. The court described the remaining year-end payment as approximately $7.5 million. The same offsetting process operated at Walgreens and Rite Aid in both years covered by the judgment.

A smaller commercial bill, paid for through higher Medicare drug costs. The benefit reached Caremark without a pharmacy writing it a separate refund check.

What the Part D Sponsors Reported to Medicare

Aetna and SilverScript reported individual prescription prices, but their year-end reports left out the effect of Caremark’s pharmacy pricing commitments. The court found that omission caused Medicare to subsidize inflated drug costs.

The reporting system had two parts. Prescription drug event records, commonly called PDEs, supplied prices for individual filled prescriptions. Direct and indirect remuneration reports, or DIR reports, accounted for other discounts and rebates affecting the drug cost. The court explained that these reports together had to reflect the price Caremark actually paid after the applicable concessions.

The distinction mattered because the Medicare reporting rules had changed in 2010. A difference between what a sponsor paid its PBM and what the PBM paid the pharmacy had to be reported as an administrative cost. Medicare would subsidize the pharmacy cost, rather than that retained spread.

Caremark called its pricing commitments one-way because the pharmacy did not send money back. The court found that reducing Caremark’s commercial bill had the same economic effect as a repayment under a two-way arrangement. The offset belonged in the Part D price reporting.

Are Clawbacks and DIR the Same Thing?

No. Recoupment takes money back, while DIR reporting tells Medicare about price concessions affecting drug costs. CMS’s guidance on adjustments after the point of sale gives a concrete distinction: for a drug never dispensed or a duplicate claim, the correction involves recouping the cost and deleting the PDE, rather than reporting it as DIR. Caremark’s case concerned the reporting of cross-book price concessions.

Four Drafts Became 513 False Reports to Medicare

Caremark’s draft DIR reports to Aetna and SilverScript fed the individual plan reports that Medicare used to calculate subsidies. The court counted the false reports submitted for those plans, rather than just the drafts Caremark sent to its clients.

Sponsors reported DIR for each individual insurance plan. Caremark knew its draft information would feed those submissions, and the whistleblower’s expert presented a table compiling the relevant plan reports. For someone working in sponsor reporting, that is a familiar distinction: a summary delivered to a client can feed many reports submitted to the government.

The Audit Matched Prices and Missed the Offset

Caremark relied on an investigation and audit that had reassured Aetna about its pricing. The court found that neither resolved the omitted offset.

The point-of-sale audit concluded that the price Caremark paid pharmacies matched what it charged Aetna for Part D drugs. Its scope excluded DIR reporting. The separate review of DIR relied on Caremark’s descriptions without access to the pharmacy contracts and reconciliation spreadsheets. Those descriptions omitted the offsetting provisions.

Caremark also told Medicare officials that pharmacies did not make true-up payments back to it. The court found that Caremark never explained the offset’s equivalent economic effect, leaving the agency with an incomplete picture.

We find the circularity hard to miss. Caremark withheld the provision that explained the savings, then relied on the reassurance produced without it. Matching the payment at the pharmacy counter left the year-end benefit untouched.

The Instruction to Stop Connecting the Books

Caremark’s own internal guidance addressed the connection that its external explanations left out. In 2014, it told employees involved in pricing negotiations with Part D sponsors or network pharmacies not to create:

The court treated the instruction as evidence supporting the False Claims Act case. Earlier internal slides had discussed how higher Part D prices and lower commercial prices would meet the overall pharmacy rate.

The reporting officer’s testimony exposed another gap. He certified that Caremark had reported all pharmacy price concessions to Aetna without reviewing the pharmacy contracts or reconciliation spreadsheets. He also lacked an understanding of how the combined commercial and Part D commitments were reconciled. The court found that signing without checking the underlying records was reckless. In its penalty opinion, it found that Caremark acted for financial gain and concealed how its pharmacy contracts worked.

How the Court Calculated the Judgment

The court assessed $95 million in actual damages, measuring the difference between the subsidies CMS paid and what it would have paid had the reports reflected Caremark’s pharmacy pricing commitments. The August decision tripled those damages to $285 million and added $4,873,500 in civil penalties, at $9,500 per false report.

That calculation connects the pharmacy pricing to the government’s loss. A reduced commercial reconciliation payment explains Caremark’s benefit. The subsidy calculation explains the damage to Medicare.

The Records That Reconnect the Books

The evidence connected pharmacy contracts, year-end reconciliation workbooks, internal pricing plans and sponsor reports. Together, they showed how the rates were set, how the offset reduced Caremark’s obligation and what the sponsors reported afterward.

The trial opinion describes the workbooks behind the Walgreens and Rite Aid reconciliations and a pricing slideshow showing planned differences between commercial and Part D rates. Those materials gave the court a view across the books that a point-of-sale comparison lacked. The reporting attestations then connected Caremark’s information to Aetna’s and SilverScript’s federal submissions.

People working in health care contracting, pricing and reporting see different parts of that process. A pharmacy contract negotiator understands the annual minimum and offset terms. A pricing analyst sees how individual MAC rates move toward the annual target. A finance or sponsor-reporting employee sees the reconciliation and the information passed onward. The actuary who brought this case began with a comparison of prices. Our work with an insider is to connect that view to the agreements, calculations and reporting decisions that explain it.

Other Part D Cases Followed Different Missing Discounts

Elixir’s rebate settlement concerned a different way of leaving money out of DIR reports. The government alleged that Elixir classified retained manufacturer rebates as service fees and excluded them from annual reporting. Rite Aid and Elixir agreed to a $101 million settlement obligation to resolve those allegations. The comparison with Caremark is the reporting gap: a pharmacy offset in one case, retained manufacturer rebates in the other.

RxAmerica agreed to pay $5.25 million to resolve allegations that it supplied false drug prices to Medicare’s Plan Finder. The government alleged that beneficiaries used that information to choose plans, while later claims sometimes carried substantially higher prices. That case followed the price from an enrollment comparison to a later claim. Caremark’s case followed it from a pharmacy agreement through reconciliation to the sponsor’s report. The useful question in each is which price was represented, to whom, and how it affected payment.

A Whistleblower’s Share of the Recovery

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In Caremark, an actuary in Aetna’s Medicare department brought the case, and the government declined to join it.

You Can See Where the Books Meet

If you work in healthcare and know how a PBM’s commercial and Medicare prices connect, talk with our whistleblower experts about the connection. We work beside you to build your strongest PBM whistleblower case around the pricing decisions and bring in PBM fraud whistleblower lawyers who understand Part D reporting and pharmacy reconciliation. From the first conversation through the pursuit of a recovery, you have experts on your side who can follow both the numbers and the business behind them.